← Human Trials & Peer-Reviewed Studies
A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly
Plain-language guide to PMID 17941902 (2008): crossover randomized controlled trial study of Octreotide and Somatostatin in 10 patients.
Key Facts
- PMID
- 17941902
- Journal
- Clinical endocrinology
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Andries M et al. (5 authors)
- DOI
- 10.1111/j.1365-2265.2007.03067.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Octreotide and Somatostatin, published as a randomized controlled trial.
To compare the effect of LAN and OCT for the treatment of acromegaly in a randomized study design.
Why It Was Studied
Somatostatin analogues have been used successfully for the treatment of acromegaly but no randomized studies have compared the effects of lanreotide Autogel (LAN) and octreotide acetate long-acting repeatable (OCT).
Who Took Part
The study group was 10 patients.
The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults, both men and women.
Twelve acromegalic patients were included and 10 patients completed treatment with LAN or OCT for 6 months and were then switched to the opposite treatment modality for 6 months without a washout period in a randomized crossover design.
How the Study Was Run
The design is described as randomized and crossover.
The patients were allocated by chance, so the Octreotide group and the comparison group should start out alike.
In the crossover set-up each of the patients took both Octreotide and the comparison in turn, acting as their own control.
The methods mention a period of 6 months.
GH and IGF-I profiles, clinical and biochemical evaluations were performed at 0, 4, 6, 10 and 12 months.
What Was Measured
Topics PubMed links to this paper include Acromegaly, Human Growth Hormone, Insulin-Like Growth Factor I, Octreotide, Peptides, Cyclic and Somatostatin.
What This Means in Plain Language
The paper is a randomized and crossover study of Octreotide and Somatostatin in 10 patients over 6 months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2008 (Clinical endocrinology), a journal based in England.
More context: the Octreotide compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.